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COX deﬁciencyMaintenance and replication of mitochondrial DNA require the concerted action of several factors encoded by
nuclear genome. The mitochondrial helicase Twinkle is a key player of replisome machinery. Heterozygous
mutations in its coding gene, PEO1, are associated with progressive external ophthalmoplegia (PEO)
characterised by ptosis and ophthalmoparesis, with cytochrome c oxidase (COX)-deﬁcient ﬁbres, ragged-red
ﬁbres (RRF) and multiple mtDNA deletions in muscle. Here we describe clinical, histological and molecular
features of two patients presenting with mitochondrial myopathy associated with PEO. PEO1 sequencing
disclosed two novel mutations in exons 1 and 4 of the gene, respectively. Although mutations in PEO1 exon 1
have already been described, this is the ﬁrst report of mutation occurring in exon 4.t no competing interests exist.
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Multiple deletions of mitochondrial DNA (mtDNA) are associated
with different mitochondrial disorders inherited as Mendelian autoso-
mal dominant and recessive traits. Causativemutationshavebeen found
in seven genes, mainly involved in mtDNA replication and stability
maintenance. They include POLG1 (encoding the catalytic subunit of
mtDNA γ-polymerase) [1], POLG2 (encoding its accessory subunit) [2],
SLC25A4 (encoding the adenine nucleotide translocator ANT1) [3], PEO1
(which encodes for Twinkle, a key helicase involved in mtDNA
replication) [4], TYMP (encoding thymidine phosphorylase) [5], OPA1
(encoding a dynamin-related GTPase linked to mitochondrial fusion)
[6,7] and RRM2B (encoding the p53-R2 subunit of ribonucleotide
reductase) [8].
Recessive PEO1 mutations result in severe and early clinical
presentations such as infantile-onset spinocerebellar ataxia [9] and
a hepatocerebral mtDNA depletion disorder [10,11]. Conversely,dominantly inherited mutations account for autosomal dominant
progressive external ophthalmoplegia (adPEO) characterised by
ptosis and ophthalmoparesis, with COX-deﬁcient and ragged-red
ﬁbres and multiple mtDNA deletions in muscle [12].
We previously reported that PEO1mutations occur in 17.9% of PEO
cases in a large cohort of patients with muscle multiple mtDNA
deletions [13].
Here we present clinical and molecular features of two indepen-
dent probands mainly showing ptosis and PEO. Two novel mutations
were detected in PEO1 affecting exon 1 and, for the ﬁrst time, exon 4,
respectively.
2. Methods
2.1. Patients
Patient 1 is a 43-year-old woman who came to our observation at
age 20 years with a ﬁve-year history of progressive bilateral ptosis
without diplopia and minimal bilateral ophthalmoplegia with
referred worsening at the end of day. For this reason she underwent
diagnostic screening for Myasthenia Gravis (EMG with repetitive
stimulation and jitter, anti-acetylcholine receptor antibody dosage),
whichwas normal. She therefore underwent skeletal muscle biopsy of
left brachial biceps muscle. Both ptosis and ophthalmoplegia got
worse in the following two years, thereafter she refused any medical
follow-up and she did not change her mind even when we contacted
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we were able to contact her 76 years old mother and 79 years old
father who, though initially reluctant, ﬁnally agreed in coming to our
Outpatient Department to undergo clinical and genetic assessment.
Their neurological examination is normal and their clinical history is
poor (the mother suffers from migraine with aura and the father has
mildly elevated blood pressure and benign prostatic hypertrophy).
Talking with them we came to know that their daughter got
progressively worse in terms of both ptosis and ophthalmoparesis
to the point that her driving licence was recalled. She is otherwise
strong and healthy with no overt medical problems (she refuses any
medical follow-up). She got married 13 years ago and has an 11 years
old healthy daughter whose picture, taken at age 10 years, does not
show any eyelid ptosis.
Patient 2 is a 39-year-old woman with a several-year history of
familial thyroid-hormone resistance syndrome (mother and a
34 years old brother also affected). She did not have any neuromus-
cular problems until 27 years of age, when she developed mild left
ptosis which got progressively worse with involvement, nine years
later, of the contralateral eyelid. Neurological examination now shows
bilateral ptosis, external ophthalmoplegia in all gaze directions with
occasional ﬁxation diplopia in the upward gaze, mild weakness of eye
orbicular muscles and moderate proximal lower limb weakness
(ileopsoas muscle). She refers easy fatigability, but denies dyspnoea,
dysphonia or dysphagia. EMG examination shows mild myopathic
signs in orbicularis oculi and orbicularis orismuscles, as well as in limb
girdle and proximal muscles of all four limbs. Cardiological examina-
tion, including EKG and echocardiography, is normal and so are serum
CK and glycemia levels. At age 37 years she underwent left brachial
biceps muscle biopsy.
Family history is negative for similar problems, her mother died in
her ﬁfties of cardio-pulmonary complications (she was affected with a
severe form of chronic obstructive–restrictive bronchopneumopathy
and secondary cardiopathy) and her father, whose parents were ﬁrst
cousins, is healthy. Her older sister is also healthy, whereas her
34 years old brother underwent the insertion of a pace-maker at age
28 years for cardiac arrest. He also had thyroid-hormone resistance
syndrome, but did not have PEO, ptosis, muscle weakness or any
central nervous system involvement.2.2. Histochemical studies
After obtaining written informed consent, left biceps skeletal
muscle biopsies were performed according to a protocol approved by
the Institutional Review Board of the “IRCCS Foundation Ca’ Granda
Ospedale Maggiore Policlinico”. 8 μm cryostatic cross sections were
processed according to standard histological/histochemical tech-
niques. Mitochondrial enzymatic activity was demonstrated by COX,
SDH and double reaction for COX and SDH [14].
The percentage of ﬁbres lacking COX activity was calculated on
skeletal muscle sections double-stained for COX and SDH. In detail, we
counted the number of COX-positive and COX-negative/deﬁcient
ﬁbres in at least 20 different ﬁelds of about 100 ﬁbres each for every
patient. For each muscle biopsy, the selected ﬁelds belonged to two
sections from different muscle samples.2.3. Molecular studies
Southern blot analysis of musclemitochondrial DNA and PCR assay
for multiple deletions were performed as described [15].
The coding sequences and splicing sites of SLC25A4, PEO1
(C10ORF2), POLG1, POLG2 and RRM2B genes were analysed as
previously described [13]. GenBank reference sequence for human
PEO1 is NM_021830.4.3. Results
Muscle histochemistry on Patient 1 revealed absence of COX
activity in several scattered muscle ﬁbres, many of which also showed
mitochondrial proliferation (intense SDH-positivity, RRFs). The
percentage of COX-negative ﬁbres was estimated at 10%.
Histochemical studies on muscle from Patient 2 showed absent or
severely reduced COX activity in several muscle ﬁbres, half of which
were ragged red. Considering both COX-negative and severely COX-
deﬁcient ﬁbres, the percentage of ﬁbres lacking COX activity was
higher than 40% (Fig. 1A).
Southern blotting and long-PCR analysis on muscle-derived
mtDNA molecules from the two probands showed the presence of
several bands corresponding to multiple-deleted genomes (Fig. 1B
and C).
PEO1 sequencing, together with SLC25A4, POLG2 and RRM2B gene
analysis, was performed after the initial screening for POLG1
mutations resulted negative. Molecular analysis revealed two novel
heterozygous mutations: c.1133TNC (exon 1) in Patient 1 and
c.1609TNC (exon 4) in Patient 2, which are likely to result in p.
Leu378Pro and p.Tyr537His changes at the protein level, respectively
(Fig. 1D). The novel variants were absent in a cohort of 279 Italian and
145 pan-ethnics control subjects as well as in public available
databases. The variant c.1133TNC was absent in both the parents of
Patient 1 suggesting it arose de novo in the proband. The variant
c.1609TNC was not found in blood-extracted DNA from the healthy
father and two siblings of Patient 2. Maternal DNA was not available
for molecular analysis.
4. Comment
Although the number of mitochondrial disorders caused by
genetically deﬁned defects of nuclear genes is still relatively small,
great progress in this ﬁeld has been made in recent years [16]. In
particular, we gained an extensive (although far from complete)
knowledge of nuclear encoded factors involved in mtDNA replication
and stability. Mutations affecting some of these factors (POLG1, PEO1,
and RRM2B) are associatedwith paediatric severe presentations when
inherited according to a recessive pattern [17]. Conversely, domi-
nantly inherited mutations result in an adult-onset mitochondrial
disease, featuring PEO and ptosis at the clinical level and the
accumulation of mtDNAmultiple deletions in muscle at the molecular
level [1,4,8]. As previously observed in our cohort of PEO patients,
POLG1 represents themost commonlymutated gene (19.4%) followed
by PEO1 (17.9%), while mutations in ANT1 are relatively rare [13]. As
far as familial PEO is concerned, the involvement of PEO1 is evenmore
signiﬁcant: the occurrence of mutations increases to 26.8% of adPEO
patients in our cohort.
Fratter and colleagues presented the clinical and laboratory
ﬁndings in a large cohort of 33 adPEO patients, investigating their
phenotypic spectrum. They disclosed a number of PEO1 molecular
defects in 16 probands from 26 unrelated families [18]. A literature
review of PEO1-mutated patients has been recently reported along
with the description of a novel French family affected with adPEO
[19].
Considering the clinical reports so far described, it is now possible
to outline some conclusions: i) PEO1 mutations are more frequent in
adult-onset cases than in paediatric subjects; ii) the most common
clinical features are PEO and ptosis, whilst syndromic features and
central nervous system involvement are less frequent than in other
genetic backgrounds, such as in POLG1-mutated patients; iii) clinical
onset of patients with PEO1 dominant mutations is often before the
ﬁfth decade (two thirds of the reported cases); iv) histochemical
analysis of muscle biopsy conﬁrms the presence of COX-deﬁcient
ﬁbres in most but not all the patients; v) detection of mtDNA-deleted
molecules in muscle tissue is often, but not always, observed.
Fig. 1. A: Histochemical double staining for COX and SDH shows severe COX deﬁciency and evidence of RRFs (Patient 2, 40X). B: Southern blot analysis of muscle-derived mtDNA of
Patient 2, two positive controls (POLG1-mutated patients) and a negative control (adult healthy subject). The black arrow indicates wild type molecules of 16.6 kb. The red arrow
indicates bands with a lower molecular weight corresponding to deleted mitochondrial genomes. C: PCR analysis of muscle-derived mtDNA of Patient 2, two positive controls and a
negative control. Red arrows indicate products of ampliﬁcation corresponding to deleted mitochondrial genomes. D: Electropherograms showing novel variants identiﬁed in Patient
1 (c.1133TNC) and Patient 2 (c.1609TNC) resulting in p.Leu378Pro and p.Tyr537His, respectively. The affected residues in the Twinkle protein are highly conserved in different
species. Hs: Homo sapiens, MaMu: Macaca mulatta; Mm: Mus musculus; Cf: Canis familiaris; Ec: Equus caballus; Xl; Xenopus laevis; Dm: Drosophila melanogaster.
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associated with PEO. Our patients are two women presenting with
ptosis and progressive ophthalmoparesis. The onset was at age 15 and
27 years respectively. Laboratory investigations revealed a marked
defect in COX activity and the accumulation of mtDNA multiple
deletions in skeletal muscle in both of them.
The mutation p.L378P affects a conserved residue located in T7
primase/helicase linker region, a known hot-spot for adPEO-linked
mutations.
On the other hand, the variant p.Y537H is, to our knowledge, the
ﬁrst mutation arose in PEO1 exon 4 ever described so far. Indeed, all
previously identiﬁed PEO1 heterozygous mutations were found in
exons 1 and 2 suggesting that mutations at the 3′ end of the gene areeither lethal or more tolerated than mutations at the NH2 terminus.
Nevertheless, the C-terminus region of Twinkle harbours the Walker
A and B motifs and the DNA binding loops: these domains are very
well conserved across species because of their critical importance for
the protein function; therefore a mutation occurring in this region
might affect not only the structure but also directly target the
functionality of the enzyme.
Matsushima and colleagues demonstrated that Drosophila mu-
tants carrying carboxyl-terminal changes display a dose-dependent
depletion of mtDNA in vitro and in vivo [20].
The tyrosine residue at position 537 is part of a highly conserved
module across higher eukaryotes except for Drosophila, in which it's
replaced by a serine.
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for the identiﬁed variants, some elements support their causative role
in producing PEO: i) they are not found in a wide number of ethnic-
matched and pan-ethnics control subjects; ii) healthy siblings of the
patients don't harbour the mutations; iii) the variants affect residues
located in regions important for a proper structure and function of
Twinkle; iv) the signs of mitochondrial pathology disclosed in our
patients are related to an impairment in mtDNA replication and their
early age of onset is compatible with PEO1mutations; v) the screening
of other PEO-associated genes was negative.
Hence, it's likely that the molecular defects here described
contribute to the heterogeneity of PEO1 mutations leading to human
mitochondrial disease. Molecular ﬁndings in Patient 2 underline the
importance of a complete sequence analysis of PEO1 coding regions.
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